Introduction
============

Crohn's disease (CD) is an inflammatory bowel disease (IBD) that affects the ileum, colon or both and may involve other parts of the gastrointestinal tract and/or have extra-intestinal manifestations. It is a progressive, destructive and currently incurable condition that is more prevalent in Europe and North America, where it affects between 10 and 150 in 100,000 persons, with a higher prevalence in women than in men \[[@goz010-B1]\].

Treatment is aimed at achieving sustained clinical remission and preventing cumulative tissue damage and subsequent disease-related complications \[[@goz010-B2]\]. Medical treatment is the primary therapeutic approach \[[@goz010-B3]\], though surgical management is essential in patients who fail to respond to medical therapy and in those who present intra-abdominal abscesses, perianal or internal fistulas, bowel obstruction or cancer \[[@goz010-B4]\]. Intestinal resection rates in CD range between 19% and 61% in the first 5 years after diagnosis and can reach 80% in the first 20 years after diagnosis, with recent studies suggesting a decline in the frequency of surgery \[[@goz010-B5]\]. The risk factors for surgery in CD are current smoking, penetrating and stricturing disease, early treatment with corticosteroids, ileal or jejunal disease and young age at diagnosis \[[@goz010-B1], [@goz010-B9]\]. Relapses are common, with post-operative recurrence affecting about 30% of patients despite prophylaxis \[[@goz010-B10]\]; approximately 14% of patients require re-intervention in the first 5 years after surgery and 30% in the first 10 years after surgery \[[@goz010-B11]\].

Surgery is associated with post-operative complications (POCs), the risk of which depends on several factors, such as disease pattern (perforating disease is associated with a higher risk of POCs), type of anastomosis, surgeon's experience, type of surgery (elective vs. urgent, open vs. laparoscopic) and other factors \[[@goz010-B12]\]. The aim of our study was to describe the prevalence of and the risk factors associated with early POCs (ePOCs) in a cohort of patients who underwent intestinal resection for CD.

Methods
=======

Study design
------------

We retrospectively reviewed the records of patients at 26 Spanish IBD units. No data were collected prospectively. The study was approved by the corresponding Research Ethics Committees.

Patient selection
-----------------

We identified patients from IBD outpatient clinics aged more than 18 years who underwent ileocolonic resection with ileocolonic anastomosis for CD between January 2007 and December 2010. Those who signed an informed consent authorizing the use of their clinical data for research were included. For this analysis, patients' data from diagnosis of CD to the index surgery and until 5 years after the index surgery were collected from medical records. All surgeries were performed with anastomosis; no surgeries with stomas were included. When the patient had undergone more than one procedure, the index surgery was considered that closest to December 2010. Data collected from the medical records included demographic data (age, sex, smoking status and family history) and clinical data (date of diagnosis, Montreal classification at diagnosis and at time of surgery \[[@goz010-B13]\], extra-intestinal manifestations, immune-mediated inflammatory diseases, IBD-related treatments received before surgery \[from diagnosis to surgery\] and at the time of surgery, approach \[open or laparoscopic\], previous surgeries, reason for current surgery \[penetrating or stricturing disease or resistance to treatment\], length of resection and hospital stay). We evaluated the rate of ePOCs during the 30 days after surgery, including death, ileus, anastomotic leak, digestive bleeding, abscess, wound infection, catheter-related infection and other extra-abdominal infections. We performed a separate analysis of infectious complications (wound infections, intra-abdominal abscesses, extra-abdominal infections and catheter-related infections). Finally, we analyzed the number of surgeries performed at each site during the study period and the influence of IBD drugs on ePOCs at the time of surgery. The rate of post-operative recurrence in this sample of patients has been reported elsewhere \[[@goz010-B10]\].

Statistical analysis
--------------------

The sample size was calculated based on the primary endpoint of the PRACTICROHN study, namely the rate of disease recurrence at 52 weeks after surgery, and has been published elsewhere \[[@goz010-B10]\]. The *t*-test, analysis of variance or nonparametric tests (Mann--Whitney test) were used to compare continuous variables. Categorical variables were compared using the χ^2^ test or Fisher's exact test, if needed.

Missing values and their frequency were tabulated but included in calculating the percentages. In all cases, the distribution of variables according to theoretical models was verified with the Kolmogorov--Smirnov test and the assumption of homogeneity of variance was contrasted using Levene's test.

Logistic-regression analysis was performed to study which baseline characteristics correlated with the variables of interest (primary and secondary objectives). Models were compared based on baseline clinical variables and surgical characteristics using a maximum-likelihood test, with an evaluation of possible interactions. Variables with *P *\<* *0.15 in the bivariate analysis were selected for the multivariate analysis. Statistical significance was set at *P *\<* *0.05.

Results
=======

Baseline characteristics
------------------------

Data from 364 CD patients were analyzed with a median age at time of surgery of 38 years (interquartile range \[IQR\] 30--48). The patients' demographic and clinical characteristics are summarized in [Table 1](#goz010-T1){ref-type="table"}. At the time of surgery, 90 (24.7%) patients had been exposed to corticosteroids, 165 (45.3%) to immunomodulators and 64 (17.6%) to biological treatments. Median time of hospitalization was 10 days (interquartile range \[IQR\] 7--14). After surgery, 27 patients had residual disease (7.4%). All patients underwent open surgery, except for 2 patients who underwent laparoscopy (data available for 300 patients).

###### 

Patients' demographic and clinical characteristics

  Characteristic                                                  All patients[^a^](#tblfn2){ref-type="table-fn"} (*n* = 364)   Without ePOCs (*n* = 263)   With ePOCs (*n* = 100)   *P*-value
  --------------------------------------------------------------- ------------------------------------------------------------- --------------------------- ------------------------ -----------
  Male gender                                                     182 (50.0)                                                    126 (47.9)                  55 (55.0)                0.276
  Age at time of diagnosis, years                                 28 (22--39)                                                   28 (22--38)                 30 (24--44)              0.042
  Time between diagnosis and surgery, years                       6 (1--12)                                                     7 (1--12)                   5 (0.8--12)              0.197
  Age at time of resection, years                                 38 (30--48)                                                   37 (29--47)                 39 (31--51)              0.119
  Active smokers at time of resection                             128 (35.2)                                                    97 (36.9)                   30 (30.0)                0.836
  Number of previous surgeries                                                                                                                                                       0.745
   0                                                              290 (79.7)                                                    211 (80.2)                  78 (78.0)                
   ≥1                                                             74 (20.3)                                                     52 (19.8)                   22 (22.0)                
  Location at time of resection                                                                                                                                                      0.474
   L1 ± L4                                                        199 (54.7)                                                    145 (55.1)                  53 (53.0)                
   L2 ± L4                                                        6 (1.6)                                                       3 (1.1)                     3 (3.0)                  
   L3 ± L4                                                        159 (43.7)                                                    115 (43.7)                  44 (44.0)                
  Behaviour at time of resection                                                                                                                                                     0.883
   B1                                                             32 (8.8)                                                      22 (8.4)                    10 (10.0)                
   B2                                                             184 (50.5)                                                    134 (51.0)                  50 (50.0)                
   B3                                                             145 (39.8)                                                    105 (39.9)                  39 (39.0)                
  Perianal disease at time of resection                           37 (10.2)                                                     25 (9.5)                    12 (12.0)                0.607
  Perianal disease at any time during the disease                 65 (17.9)                                                     49 (18.6)                   16 (16.0)                0.603
  Length of resection                                                                                                                                                                0.243
   ≤50 cm                                                         248 (68.1)                                                    177 (67.3)                  71 (71.0)                
   \>50 cm                                                        38 (10.4)                                                     23 (8.7)                    15 (15.0)                
  Extra-intestinal manifestations between diagnosis and surgery   45 (12.4)                                                     31 (11.8)                   14 (14.0)                0.651
  Indication for surgery                                                                                                                                                             0.018
   Penetrating                                                    114 (31.3)                                                    77 (29.3)                   36 (36.0)                
   Stricturing                                                    169 (46.4)                                                    124 (47.1)                  45 (45.0)                
   Penetrating + stricturing                                      51 (14.0)                                                     45 (17.1)                   6 (6.0)                  
   Resistance to treatment                                        21 (5.8)                                                      12 (4.6)                    9 (9.0)                  
  Medication prior to surgery                                                                                                                                                        
   Corticosteroids                                                174 (47.8)                                                    134 (51.0)                  39 (39.0)                0.043
   Immunomodulators                                               73 (20.1)                                                     57 (21.7)                   16 (16.0)                0.305
   Anti-TNF                                                       68 (18.7)                                                     51 (19.4)                   17 (17.0)                0.736
   More than 1 medication                                         81 (22.3)                                                     62 (23.6)                   19 (19.0)                0.379
  Medication at the time of surgery                                                                                                                                                  
   Corticosteroids                                                90 (24.7)                                                     62 (23.6)                   28 (28.0)                0.493
   Immunomodulators                                               165 (45.3)                                                    119 (45.2)                  46 (46.0)                0.937
   Anti-TNF                                                       64 (17.6)                                                     42 (16.0)                   22 (22.0)                0.218
   More than 1 medication                                         90 (24.7)                                                     62 (23.6)                   28 (28.0)                0.434
  Time from diagnosis to surgery                                                                                                                                                     0.013
   \<1 month                                                      31 (8.5)                                                      16 (6.1)                    15 (15.0)                
   ≥1 month                                                       331 (90.9)                                                    245 (93.2)                  85 (85.0)                
  Length of hospitalization, days                                 10 (7--14)                                                    9 (7--11)                   16 (10--28)              \<0.001

ePOCs, early post-operative complications; TNF, tumour necrosis factor.

There is one patient with missing data regarding having ePOC or not.

Values presented as median (interquartile range) or number (%).

Early POCs
----------

At least one ePOC was recorded in 100 patients (27.5%). Wound infection (*n* = 33, 9.1%), intra-abdominal abscess (*n* = 28, 7.7%) and anastomotic leak (*n* = 27, 7.4%) were the most common ePOCs ([Table 2](#goz010-T2){ref-type="table"}). There were no deaths within 30 days after surgery. Median hospital stay for patients with ePOCs was 16 days (IQR 10--28) compared with 9 days (IQR 7--11) for patients without ePOCs (*p *\<* *0.001). As for the experience of the centres in IBD-related surgery, only 20 out of 26 centres had data on the number of IBD-related surgeries performed during 2007--10. We found no difference in the rate of ePOCs related to the number of surgeries performed in each hospital (32% in hospitals with \<30 surgeries, 25% in hospitals with 31--60 surgeries and 26% in hospitals with \>60 surgeries; *P *=* *0.40). The only type of ePOC that was more frequent in hospitals with a lower number of IBD-related surgeries was anastomotic leak (15.2% in hospitals with \<30 surgeries performed vs. 5.9% in hospitals with 31--60 surgeries and 3.5% in hospitals with \>60 surgeries; *P *=* *0.001) ([Table 2](#goz010-T2){ref-type="table"}).

###### 

Number of patients with early post-operative complications (ePOCs)

  Event                              All patients (*n* = 364)                        Number of IBD surgeries performed between 2007 and 2010                           
  ---------------------------------- ----------------------------------------------- --------------------------------------------------------- ----------- ----------- -------
  Any complication                   100 (27.5)[^a^](#tblfn4){ref-type="table-fn"}   34 (32.4)                                                 21 (24.7)   44 (25.9)   0.404
  Death                              0 (0)                                           0 (0)                                                     0 (0)       0 (0)       --
  Ileus                              11 (3.0)                                        6 (5.7)                                                   1 (1.2)     3 (1.8)     0.122
  Digestive bleeding                 11 (3.0)                                        3 (2.9)                                                   2 (2.4)     6 (3.5)     0.927
  Anastomotic leak                   27 (7.4)                                        16 (15.2)                                                 5 (5.9)     6 (3.5)     0.001
  Intra-abdominal abscess            28 (7.7)                                        11 (10.5)                                                 5 (5.9)     12 (7.1)    0.446
  Wound infection                    33 (9.1)                                        10 (9.5)                                                  6 (7.1)     17 (10.0)   0.737
  Catheter-related sepsis            4 (1.1)                                         0 (0)                                                     2 (2.4)     2 (1.2)     0.270
  Other extra-abdominal infections   12 (3.3)                                        2 (1.9)                                                   3 (3.5)     7 (4.1)     0.693

There is one patient with ePOC missing data regarding number of surgeries performed on this site.

There were no associations between the incidence of ePOCs and the length of intestinal resection, sex, age at time of surgery, history of previous surgeries, location of disease, presence of perianal disease, disease behaviour or smoking status ([Table 1](#goz010-T1){ref-type="table"}). Regarding treatments received before surgery, we found that patients without ePOC more frequently received corticosteroids before surgery than patients with ePOC 39 (51.0% vs. 39.0%, *P *=* *0.043), with no difference in the rate of ePOCs found with other treatments. Nevertheless, at the time of surgery, we found no differences in the rate of ePOCs with any of the treatments received ([Table 1](#goz010-T1){ref-type="table"}). The main reason for surgery was stricturing disease, both in patients with ePOCs (45.0%) and without ePOCs (47.1%); however, the incidence of ePOCs was higher in patients with intestinal perforation as the indication for surgery (36/114, 31.6%), as was being refractory to treatment (9/21, 42.9%), than in those with stricturing disease (alone or in combination with penetrating disease), which was associated with a lower risk of ePOCs (45/169, 26.6% and 6/51, 11.8%, respectively) (*P *=* *0.040) ([Figure 1](#goz010-F1){ref-type="fig"}). We also analyzed the relationship between time from diagnosis to surgery and the presence of ePOCs and found that ePOCs were more common in patients with surgery performed in the month following the diagnosis of CD (15/31, 48.4%) than in patients who were operated on when the diagnosis of CD had been already established (85/331, 25.7%; *P *=* *0.013) ([Figure 1](#goz010-F1){ref-type="fig"}).

![Percentage of patients with and without early post-operative complications (ePOCs) according to cause for surgery and time from diagnosis to surgery. The dotted lines correspond to the percentages of patients without and with ePOCs in the overall study population (68.4% and 31.6%, respectively).](goz010f1){#goz010-F1}

Multiple logistic-regression analysis showed no association between the risk of ePOCs and the following independent variables: age at time of surgery, sex, reason for surgery, emergency surgery and number of surgeries performed at each site ([Table 3](#goz010-T3){ref-type="table"}).

###### 

Logistic-regression results

  Explicative variables                                Coefficient (95% confidence interval)   Odds ratio   Z-value   *P*-value
  ---------------------------------------------------- --------------------------------------- ------------ --------- -----------
  Intercept                                            --0.42 (--1.51, 0.67)                   0.65         --0.760   0.447
  Age at surgery                                       0.02 (0, 0.04)                          1.02         1.818     0.069
  Gender: female                                       --0.30 (--0.8, 0.2)                     0.74         --1.164   0.244
  Indication for surgery: stricturing                  --0.16 (--0.72, 0.41)                   0.86         --0.546   0.585
  Indication for surgery: penetrating + stricturing    --1.05 (--2.1, --0.14)                  0.35         --2.120   0.034
  Indication for surgery: resistance to treatment      0.61 (--0.41, 1.62)                     1.85         1.196     0.232
  Number of surgeries performed at each site: 31--60   --0.29 (--0.98, 0.38)                   0.75         --0.839   0.401
  Number of surgeries performed at each site: \>60     --0.26 (--0.82, 0.31)                   0.77         --0.887   0.375
  Time from diagnosis to surgery ≥1 month              --0.90 (--1.7, --0.09)                  0.41         --2.183   0.029

Treatments prescribed at discharge and follow-up after surgery are summarized in [Table 4](#goz010-T4){ref-type="table"}. Patients with ePOCs were prescribed immunomodulators at discharge less frequently (*P *=* *0.025) and were monitored with imaging techniques (computed tomography or magnetic resonance imaging) more frequently (*P *=* *0.047). No other differences were found regarding the treatments received or the follow-up between patients with and without ePOCs.

###### 

Medication at discharge and follow-up after surgery

  Treatment                              All patients[^a^](#tblfn6){ref-type="table-fn"} (*n* = 364)    Without ePOC (*n* = 263)   With ePOC (*n* = 100)   *P*-value
  -------------------------------------- ------------------------------------------------------------- -------------------------- ----------------------- -----------
  Medication at discharge                                                                                                                                 
   Oral corticosteroids                  70 (19.2)                                                             47 (17.9)                 23 (23.0)           0.364
   Immunomodulators                      117 (32.1)                                                            94 (35.7)                 23 (23.0)           0.025
   Antibiotics                           77 (21.2)                                                             52 (19.8)                 25 (25.0)           0.324
   Anti-TNF                              31 (8.5)                                                               19 (7.2)                 12 (12.0)           0.213
   Aminosalicylates                      43 (11.8)                                                             32 (12.2)                 11 (11.0)           0.881
   More than 1 medication                79 (21.7)                                                             59 (22.4)                 20 (20.0)           0.722
  Follow-up after surgery                                                                                                                                 
   Days until the following visit        46.9 ± 59.9                                                          45.8 ± 52.1               46.2 ± 68.4          0.992
   Colonoscopy in the first year         140 (38.5)                                                            102 (38.8)                38 (38.0)           0.987
   Imaging technique in the first year   59 (16.2)                                                             36 (13.7)                 23 (23.0)           0.047
   Blood test in the first year          300 (82.4)                                                            214 (81.4)                86 (86.0)           0.376
   Biomarker test in the first year      44 (12.1)                                                             30 (11.4)                 14 (14.0)           0.620

ePOCs, early post-operative complications; TNF, tumour necrosis factor.

There is one patient with missing data regarding having ePOC or not.

Values presented as mean ± standard deviation or number (%).

Infectious complications
------------------------

During the first month after surgery, 69 patients (19.0%) presented with at least one infectious complication; the median length of hospital stay was 19 days (IQR 10--30) for patients with infectious complications compared with 9 days (IQR 7--12) for the remaining patients (*P *\<* *0.001). The most frequent infectious complications were wound infections (*n* = 33), intra-abdominal abscesses (*n* = 28), extra-abdominal infections (*n* = 12) and catheter-related infections (*n* = 4). No differences in the incidence of infectious complications were observed regarding age, sex, smoking status, disease location or length of intestinal resections. There was no association between medication received at surgery and the rate of infectious complications.

Discussion
==========

Surgery carries risks, including mortality and POCs. Serious POCs, such as anastomotic leak and intra-abdominal sepsis, develop more frequently after surgery for CD than other intestinal resections \[[@goz010-B14], [@goz010-B14]\]. Incidence varies with the type of complication, as follows: 0%--18.8% for wound sepsis, 3.1%--18.7% for abdominal abscess, 0%--12.7% for anastomotic leak \[[@goz010-B8], [@goz010-B16], [@goz010-B17]\] and 0.6%--3.6% for post-operative death \[[@goz010-B17]\].

In the present observational study, which was based on data from routine practice in a large sample of patients from Spain, we evaluated the rate of ePOCs following surgery for CD. We found that 27.5% of patients developed ePOCs after intestinal resection, with wound infection, abscess and anastomotic leak being the most frequent complications. Our results are in line with those of previous studies, which reported an incidence of ePOCs of 15%--30% after bowel resection in patients with CD \[[@goz010-B18]\].

It is worth mentioning that hospital experience in IBD-related surgery was not related to the rate of ePOCs, except for anastomotic leak, which was more common in hospitals with \<30 surgeries performed between 2007 and 2010 than in hospitals with \>60 surgeries performed during the same time period (*P *=* *0.001). This finding is similar to that of previous studies, where surgeon experience was associated with better outcomes \[[@goz010-B22], [@goz010-B23]\]. In our study, most of the surgeries were performed by specialized colorectal surgeons, thus explaining the low rate of differences found.

Analysis of the risk factors for ePOCs revealed that surgery performed at the time of diagnosis (probably an urgent surgery) and stricturing disease as the indication for surgery were both significantly associated in the bivariate analyses, with an increased risk of complications, and penetrating + stricturing disease (more specifically, perforation, data not shown) associated with a lower risk. The potential impact of previous medication, in particular, anti-tumour necrosis factor (TNF) drugs or corticosteroids, on the risk of ePOCs after bowel resection in CD is a matter of debate. While some studies and meta-analyses suggest that anti-TNF treatment before surgery is associated with a higher rate of ePOCs, especially infectious complications \[[@goz010-B24]\], others find no increased risk \[[@goz010-B20], [@goz010-B27], [@goz010-B28]\]. In our study, we found no association between the risk of ePOCs and the use of anti-TNF drugs. In that sense, the number of patients receiving anti-TNF treatment at surgery 64 (17.6%) is similar to the study of Colombel *et al.* \[[@goz010-B29]\], with 19% of patients receiving anti-TNF treatment at surgery. In Colombel's study, no difference was found either in the number of patients presenting ePOC between those with and without anti-TNF treatment at surgery. During the study period, no other biologics were allowed for CD treatment, hence no comparisons with vedolizumab could be made. A comparison with vedolizumab would have been interesting, given that treatment with this agent, which targets α4β7 integrin, has been associated with a greater risk of ePOCs (53%) than treatment with TNF inhibitors (33%) or no biological therapies (28%) \[[@goz010-B30]\].

Several observational studies identified pre-operative corticosteroid treatment as a risk factor for POCs \[[@goz010-B28], [@goz010-B31], [@goz010-B32]\]; however, high-quality studies on the subject are lacking. We found that treatment with corticosteroids at the time of surgery was not associated with a higher risk of early POCs. Though the number of patients may have been insufficient to detect differences, we concomitantly found that corticosteroid use before surgery was associated with a lower rate of ePOCs. This could be explained by the fact that, while, during the treatment, 47.8% of patients received treatment with corticosteroids, at the exact time point of the surgery, only 24.7% of patients were receiving treatment with steroids. That reflects an important withdrawal of corticosteroid use and the patients who remained on corticosteroids likely used the minimum dose possible. Unfortunately, we did not collect information on the dose of corticosteroid used, so we cannot assure this point.

Other factors have been linked to POCs after CD-related intestinal resection. Thus, several studies and meta-analyses focused on the surgical approach and technique: 3 meta-analyses of up to 15 studies showed the post-operative benefits of the laparoscopic approach \[[@goz010-B33]\], including a decreased rate of POCs and shorter hospital stay, faster return to normal activity and diet, better cosmesis and improved social and sexual interaction. Another meta-analysis concluded that stapled side-to-side anastomosis was linked to fewer overall POCs and a lower recurrence and re-operation rate than end-to-end hand-sewn anastomosis \[[@goz010-B36]\]. In our sample, only two patients underwent laparoscopy, thus implying that our results only apply to open abdominal surgery. Furthermore, since information on the type of anastomosis was not collected in our study, we cannot compare the frequencies of ePOC associated with the different techniques. Given that the laparoscopic approach is widely used in Spain today, the prevalence of ePOCs would probably be lower than that reported in this analysis.

Emergency surgery is seldom necessary in CD. However, when required, it is associated with higher rates of post-operative mortality (3.6%; 95% confidence interval \[CI\], 1.8%--6.9%) than elective surgery (0.6%; 95% CI, 0.2%--1.7%) \[[@goz010-B17]\]. We recorded no POC-related deaths, but 31 (8.5%) patients underwent surgery within 1 month of the diagnosis of CD, probably reflecting a more severe and complex disease, or emergency surgeries. In these patients, the number of ePOCs was significantly higher than in patients who had undergone surgery at least 1 month after the diagnosis. Although we cannot rule out the possibility that there were no emergency procedures in the latter group of patients, our data agree with previous reports that associate emergency surgery with an increased risk of POCs \[[@goz010-B37]\] and stress the importance of the surgeon's experience for better outcomes.

Observational studies like this one use statistical methods to identify risk factors; however, the results are more difficult to compare due to differences in study design, available information and possible confounding effects. Thus, in an observational study of 131 patients with CD, Heimann *et al.* \[[@goz010-B18]\] found that 30% experienced complications early after surgical intervention and septic complications were more common in patients with extensive resections and in those with multiple previous operations. In our study, there was no statistically significant association between length of resection and risk of POCs, though there was a trend toward a higher incidence of ePOCs among patients with extensive resections (\>50 cm). We found no additional risk of ePOCs associated with a history of previous surgeries, but the number of patients with repeat surgeries was low. A total of 74 patients had previously undergone surgery (one procedure in 70, two procedures in 2 and three procedures in 3). The number of patients with previous surgeries may have been insufficient to detect significant differences in ePOCs between them and the patients who underwent primary surgery.

In an observational study on 161 consecutive patients with CD, Alves *et al.* \[[@goz010-B38]\] found that pre-operative corticosteroids, poor nutritional status and the presence of abscess at the time of surgery significantly increased the risk of septic abdominal complications after the first ileocecal resection for CD. Similarly, in a pooled analysis of 343 patients who underwent 566 operations for primary or recurrent CD, Yamamoto *et al.* \[[@goz010-B39]\] found that intra-abdominal septic complications were significantly associated with low pre-operative albumin levels (\<30 g/L), pre-operative corticosteroids and abscess or fistula at the time of laparotomy. In the present sample, as mentioned above, therapy with corticosteroids at the time of surgery was not associated with a higher risk of POCs, whereas perforation was. Unfortunately, we recorded no data on nutritional status or albumin levels at the time of surgery. Consistently with our results, Yamamoto *et al.* found that age, duration of symptoms, number of previous bowel resections and site of disease had no effect on the risk of infectious complications. In contrast, in a large study of 2638 patients with CD and 559 patients with ulcerative colitis, Frolkis *et al.* \[[@goz010-B37]\] reported that predictors for in-hospital POCs for both diseases included older age, comorbidities, open laparotomy for CD, emergency admission, stoma surgery and concurrent resection of both the small and the large bowels. Further, well-designed, large studies with wide-ranging data are needed to better characterize the risk factors associated with POC in CD-related bowel resection.

Our study presents a series of limitations. First, owing to its retrospective design, the only data available were those from patients' medical records. Several relevant variables were not collected, including type of anastomosis (stapled vs. hand-sewn), configuration of anastomosis (end-to-end vs. side-to-side), patients' nutritional status, serum albumin levels, creatinine levels and microscopically positive resection margin, which have been recognized as risk factors for complications. Second, the complications were not classified, such as using the Clavien--Dindo classification \[[@goz010-B40]\]. As a result, we can only draw conclusions about the scope of the complications but not about their severity or impact on the patient beyond length of hospital stay. Third, the insufficient size of certain subgroups of patients may have hindered the detection of differences and precluded the identification of additional risk factors for POCs. Finally, analysing surgeries between 2007 and 2010 may not accurately reflect current management of CD, though the choice of these dates for the index surgeries did allow us to assess long-term outcomes, such as recurrence and hospital admissions over 5 years of follow-up after surgery. The study reflects clinical practice during the years when the surgeries were performed and, although clinical practice has evolved since then, our findings highlight the importance of ePOC as an event leading to longer hospital stay and thus potentially higher related health-care costs.

In conclusion, one-quarter of patients who underwent ileocolonic resection for CD experienced ePOCs. The indication for surgery and emergency surgery were the most important predictors of ePOCs.
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